内容我的课件张立.ppt

* * * * Let’s look at all event rates. * * -PROMUS Element has a dedicated small vessel 2.25 mm stent model. #PLATINUM SV Trial Presented by Dominic Allocco MD, PCR 2012. Ian T. Meredith, MBBS, PhD is the PI. +Presented by Laura Mauri MD, MSc, ACC 2012. Results from different studies are not directly comparable. Information provided for educational purposes only. PLATINUM Small Vessel Trial# PROMUS Element? Stent- (n = 89) RVD = 2.08 mm Lesion Length = 14.15 mm Incidence Rate (%) Resolute US Trial* Resolute? Stent (n = 147) RVD = 2.15 mm Lesion Length = 12.40 mm Incidence Rate (%) PLATINUM Small Vessel Trial 2-Year Clinical Results in Perspective -PROMUS Element has a dedicated small vessel 2.25 mm stent model. ^Xience V is the 2.50 - 3.00 mm model crimped to a 2.25mm balloon. #PROMUS Element Plus Stent System DFU. +Xience V Stent System DFU. *RESOLUTE Integrity Stent System DFU. Results from different studies are not directly comparable. Information provided for educational purposes only. SPIRIT Small Vessel Trial+ Xience nano? Stent^ (n = 136) RVD = 2.13 mm Lesion Length = 13.38 mm PLATINUM Small Vessel Trial# PROMUS Element? Stent- (n = 94) RVD = 2.04 mm Lesion Length = 14.15 mm Incidence Rate (%) Incidence Rate (%) Resolute US Trial* Resolute? Stent (n = 146) RVD = 2.15 mm Lesion Length = 12.40 mm Incidence Rate (%) PLATINUM Small Vessel Trial 1-Year Clinical Results in Perspective Intent-to-treat population PLATINUM Long Lesion Trial12-Month Clinical Results Study Objective: Evaluate the safety and effectiveness of the PROMUS Element? Everolimus-Eluting Coronary Stent System for the treatment of patients with a single de novo coronary artery lesion >24 and ≤34 mm in length, ≥2.50 mm to ≤4.25 mm in diameter Study Design: Prospective, single-arm, multi-center Primary Endpoint: 12-month TLF (ID-TLR or TV-CD or TV-MI) against a performance goal of 19.4% (based on historical TAXUS? Express? results) in the per protocol population Number of Patients: